O'Brien M E, Bayliss E J, Stewart M E, Smyth J F, Rodger A, Leonard R C
Department of Clinical Oncology, Western General Hospital, Edinburgh, U.K.
Cancer Chemother Pharmacol. 1990;27(1):79-80. doi: 10.1007/BF00689282.
Fifty-five patients who had relapsed or progressed from chemotherapy for advanced disease were treated with mitomycin C and 5-FU on a 6 weekly regimen. After a median of 2 cycles of therapy the overall response rate was 12% with no complete responses. Significant leucopenia but no thrombocytopenia was seen and despite the low overall response rate the regimen was tolerable and did produce responses in patients primarily resistant to Adriamycin combination chemotherapy. Low overall activity indicates the need for more effective second line treatment.
55例晚期疾病化疗后复发或进展的患者接受了丝裂霉素C和5-氟尿嘧啶治疗，采用每6周一次的治疗方案。经过中位2个周期的治疗，总缓解率为12%，无完全缓解。观察到明显的白细胞减少但无血小板减少，尽管总缓解率较低，但该方案耐受性良好，确实使对阿霉素联合化疗主要耐药的患者产生了缓解。总体活性较低表明需要更有效的二线治疗。
